Samuel D Colella - Net Worth and Insider Trading

Samuel D Colella Net Worth

The estimated net worth of Samuel D Colella is at least $39 Million dollars as of 2024-11-10. Samuel D Colella is the Director, 10% Owner of Flexion Therapeutics Inc and owns about 3,996,929 shares of Flexion Therapeutics Inc (FLXN) stock worth over $36 Million. Samuel D Colella is the Director of Genomic Health Inc and owns about 36,437 shares of Genomic Health Inc (GHDX) stock worth over $2 Million. Samuel D Colella is also the Director of Standard BioTools Inc and owns about 239,268 shares of Standard BioTools Inc (LAB) stock worth over $514,426. Details can be seen in Samuel D Colella's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Samuel D Colella has not made any transactions after 2020-03-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Samuel D Colella

To

Samuel D Colella Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Samuel D Colella owns 12 companies in total, including Flexion Therapeutics Inc (FLXN) , Standard BioTools Inc (LAB) , and Glaukos Corp (GKOS) among others .

Click here to see the complete history of Samuel D Colella’s form 4 insider trades.

Insider Ownership Summary of Samuel D Colella

Ticker Comapny Transaction Date Type of Owner
FLXN Flexion Therapeutics Inc 2020-06-10 director & 10 percent owner
LAB Standard BioTools Inc 2020-03-11 director
GKOS Glaukos Corp 2015-06-24 10 percent owner
LIMIT LIMIT 2016-05-23 10 percent owner
LIMIT LIMIT 2014-09-09 10 percent owner
LIMIT LIMIT 2014-11-18 10 percent owner
LIMIT LIMIT 2013-10-29 director & 10 percent owner
LIMIT LIMIT 2012-06-06 other: Former Director
LIMIT LIMIT 2007-05-31 director
LIMIT LIMIT 2007-05-14 10 percent owner
LIMIT LIMIT 2006-05-09 10 percent owner
LIMIT LIMIT 2014-11-18 10 percent owner

Samuel D Colella Latest Holdings Summary

Samuel D Colella currently owns a total of 3 stocks. Among these stocks, Samuel D Colella owns 3,996,929 shares of Flexion Therapeutics Inc (FLXN) as of August 8, 2019, with a value of $36 Million and a weighting of 92.81%. Samuel D Colella owns 36,437 shares of Genomic Health Inc (GHDX) as of November 20, 2012, with a value of $2 Million and a weighting of 5.89%. Samuel D Colella also owns 239,268 shares of Standard BioTools Inc (LAB) as of March 11, 2020, with a value of $514,426 and a weighting of 1.31%.

Latest Holdings of Samuel D Colella

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
FLXN Flexion Therapeutics Inc 2019-08-08 3,996,929 9.12 36,451,992
GHDX Genomic Health Inc 2012-11-20 36,437 63.44 2,311,563
LAB Standard BioTools Inc 2020-03-11 239,268 2.15 514,426

Holding Weightings of Samuel D Colella


Samuel D Colella Form 4 Trading Tracker

According to the SEC Form 4 filings, Samuel D Colella has made a total of 0 transactions in Flexion Therapeutics Inc (FLXN) over the past 5 years. The most-recent trade in Flexion Therapeutics Inc is the acquisition of 2,000 shares on August 8, 2019, which cost Samuel D Colella around $21,480.

According to the SEC Form 4 filings, Samuel D Colella has made a total of 0 transactions in Genomic Health Inc (GHDX) over the past 5 years. The most-recent trade in Genomic Health Inc is the sale of 30,616 shares on November 20, 2012, which brought Samuel D Colella around $823,264.

According to the SEC Form 4 filings, Samuel D Colella has made a total of 1 transactions in Standard BioTools Inc (LAB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Standard BioTools Inc is the acquisition of 20,000 shares on March 11, 2020, which cost Samuel D Colella around $54,200.

Insider Trading History of Samuel D Colella

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Samuel D Colella Trading Performance

GuruFocus tracks the stock performance after each of Samuel D Colella's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Samuel D Colella is -0.07%. GuruFocus also compares Samuel D Colella's trading performance to market benchmark return within the same time period. The performance of stocks bought by Samuel D Colella within 3 months outperforms 8 times out of 15 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Samuel D Colella's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Samuel D Colella

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
12 out of 15 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.99 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.5 LIMIT LIMIT LIMIT LIMIT LIMIT

Samuel D Colella Ownership Network

Ownership Network List of Samuel D Colella

No Data

Ownership Network Relation of Samuel D Colella

Insider Network Chart

Samuel D Colella Owned Company Details

What does Flexion Therapeutics Inc do?

Who are the key executives at Flexion Therapeutics Inc?

Samuel D Colella is the director & 10 percent owner of Flexion Therapeutics Inc. Other key executives at Flexion Therapeutics Inc include Chief Regulatory Officer Kerry Wentworth , Chief Strategy Officer Christina Willwerth , and General Counsel Mark S. Levine .

Flexion Therapeutics Inc (FLXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Flexion Therapeutics Inc (FLXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Flexion Therapeutics Inc (FLXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Flexion Therapeutics Inc (FLXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Flexion Therapeutics Inc Insider Transactions

No Available Data

Samuel D Colella Mailing Address

Above is the net worth, insider trading, and ownership report for Samuel D Colella. You might contact Samuel D Colella via mailing address: One Sansome Street, Suite 3630, San Francisco Ca 94104.